secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001104659-22-128310
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova adds two independent directors with pharma R&D backgrounds
-------------------------------------------------------------------

- Board expanded to eight; elected Peter Atadja (former Novartis Executive Director) and Trafford Clarke (former Eli Lilly Managing Director).
- Atadja appointed Chair of Nominating & Corporate Governance; Clarke joins Compensation Committee.
- Each receives standard non-employee director compensation plus one-time option to purchase 100,000 shares of common stock.
- Atadja led discovery/development of first approved HDAC inhibitor (FARYDAK); Clarke spent 31 years at Eli Lilly in senior R&D roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/tm2233068d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-128310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer